Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | August 2011 |
| End Date: | August 2016 |
Pilot Trial of Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
Multiple myeloma is difficult to treat with only anti-cancer medicine (called chemotherapy)
or radiation alone. Sometimes higher doses of chemotherapy are used but when used can also
lower blood counts. Using own cells (special cells called stem cells) to help increase the
blood counts after high doses of chemotherapy is called autologous stem cell transplantation
(ASCT).
Using own stem cells to restore blood counts and other advances in supportive measures
(antibiotics and growth factors that increase blood counts) has improved the safety of ASCT.
However, blood counts still decrease for a period of days after high doses of chemotherapy.
During that time, patients are at greater risk for infections. Studies have shown that the
faster the blood counts recover after ASCT, the less at risk there is for developing
unwanted side effects after ASCT.
Typically during an ASCT, a patient's stem cells are given back to them all at once on a
single day. In this study, the investigators plan to see what happens when smaller amounts
of own stem cells are given back to the patient over multiple days. The investigators want
to find out what effects good and/or bad this will have on the patient and there multiple
myeloma. Some studies have shown that giving back stem cells over a period of days helps to
increase bone marrow activity and decrease the time it takes for blood counts to recover
after ASCT. It is our hope that this new approach may lower a patient's risk of side effects
and infections, decrease the number of blood transfusions that a patient needs during this
process, reduce the time a patient has to spend in the hospital, and lower overall treatment
costs.
or radiation alone. Sometimes higher doses of chemotherapy are used but when used can also
lower blood counts. Using own cells (special cells called stem cells) to help increase the
blood counts after high doses of chemotherapy is called autologous stem cell transplantation
(ASCT).
Using own stem cells to restore blood counts and other advances in supportive measures
(antibiotics and growth factors that increase blood counts) has improved the safety of ASCT.
However, blood counts still decrease for a period of days after high doses of chemotherapy.
During that time, patients are at greater risk for infections. Studies have shown that the
faster the blood counts recover after ASCT, the less at risk there is for developing
unwanted side effects after ASCT.
Typically during an ASCT, a patient's stem cells are given back to them all at once on a
single day. In this study, the investigators plan to see what happens when smaller amounts
of own stem cells are given back to the patient over multiple days. The investigators want
to find out what effects good and/or bad this will have on the patient and there multiple
myeloma. Some studies have shown that giving back stem cells over a period of days helps to
increase bone marrow activity and decrease the time it takes for blood counts to recover
after ASCT. It is our hope that this new approach may lower a patient's risk of side effects
and infections, decrease the number of blood transfusions that a patient needs during this
process, reduce the time a patient has to spend in the hospital, and lower overall treatment
costs.
Inclusion Criteria:
- Age ≥18 and < than or = to 75
- Histologic and serologic findings, reviewed at MSKCC, confirming the diagnosis of
multiple myeloma. Standard diagnostic criteria for multiple myeloma will be used, as
per the International Myeloma Foundation consensus guidelines (Durie et al, 2003) .
- Patients must have symptomatic multiple myeloma who have responded to prior induction
or salvage chemotherapy (i.e. chemosensitive disease):
- Patients who are receiving high-dose melphalan and ASCT as part of their initial
therapy require at least minor response to their last line of therapy to
document chemosensitive disease (Anderson et al. 2008)
- Patients who are receiving high-dose melphalan and ASCT as part of salvage
therapy require at least a minor response to their last line of therapy to
document chemosensitive disease (Anderson et al. 2008).
- There is no limit on the number of prior regimens received by the patient.
- Patients must have at least 7 x 10^6 (+/- 0.5 x 10^6) CD34+ stem cells/kg
frozen if he/she is being treated as part of a salvage (second) transplant
strategy; patients must have 10 x 10^6 (+/- 0.5 x 10^6) CD34+ stem cells/kg
frozen if ASCT is being performed as part of initial therapy.
- Adequate organ function is required, defined as follows:
- Serum bilirubin ≤ 2.0 mg/dl
- AST, ALT and alkaline phosphatase < 3 times the upper limit of laboratory normal
- Creatinine clearance > or = to 40 ml/min (24 hour urine collection or
calculated*)
*To be calculated by the Cockroft-Gault method: (140-Age) x Mass (kg) x [0.85 if
female] (72 x Creatinine (mg/dL)
- LVEF > or = to 45% by MUGA or rest ECHO
- Diffusing capacity > or = to 45% (adjusted for hemoglobin) predicted by
pulmonary function testing
- Performance status KPS > or = to 70%.
Exclusion Criteria:
- Unstable angina or myocardial infarction within 4 months of initiating therapy on
trial, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled
ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of
acute ischemia or Grade 3 conduction system abnormalities unless subject has a
pacemaker
- Pregnant or lactating females
- Nonhematologic malignancy within the past 3 years with the exception of a) adequately
treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b)
carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or
less with stable prostate-specific antigen levels; or d) cancer considered cured by
surgical resection or unlikely to impact survival during the duration of the study,
such as localized transitional cell carcinoma of the bladder or benign tumors of the
adrenal or pancreas
- Contraindication to melphalan or any of the required supportive treatments, including
hypersensitivity to G-CSF or pegfilgrastim
- Any other medical condition or laboratory evaluation that, in the treating
physician's or principal investigator's opinion, makes the patient unsuitable to
participate in this clinical trial
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
